Koneksa, a leader in evidence-based digital biomarkers, announced a new publication in Clinical and Translational Science titled Syndication in Science: Curated Collaboration, in partnership with researchers from Takeda, Regeneron, and Merck.
Digital measures in clinical research offer continuous, real-time data but face adoption challenges due to validation time, costs, and evidence requirements. Koneksa’s data syndication model addresses these issues by fostering collaboration among technology providers, biopharmaceutical sponsors, and other stakeholders to share resources, accelerate study launches, and validate digital measures faster.
“The model combines the speed of single-sponsor studies with multi-member expertise and shared risk,” said John Wagner, M.D., Ph.D., Chief Medical Officer at Koneksa.
The model is being tested in the LEARNS Parkinson’s study, where wearable devices and the Koneksa neuroscience toolkit track disease progression. Partners like Merck and Regeneron collaborate to validate digital measures in real time.
“This approach advances patient-friendly, reliable digital measures,” said Dave Hurry, Chief Data Officer at Koneksa. “By streamlining validation, we’re transforming drug development through collaboration and innovation.”
Click here to read the original news story.